Over 25,650 participants have so far received their second shot of the vaccine candidate, mRNA-1273, the company said. Moderna said its study includes more than 11,000 participants from minority communities, including 6,000 Hispanic or Latin-American participants and more than 3,000 Black or African-American participants. The U.S. Food and Drug Administration requires at least two months of safety data after a full vaccination regime to review applications for emergency use authorization of an experimental vaccine.
